Clinical trial
T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the…
NCT00021554 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00021554 |
|---|---|
| Title | T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs |
| Official title | A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Regimen Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each… |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Trimeris Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Enfuvirtide |
| Enrollment | 525 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Australia, Belgium, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: